Or
Contact UsMethotrexate goes by MTX in most oncology units. It has been around long enough that its role is well established. It belongs to the antimetabolite class — a group of drugs that starve dividing cells of the materials they need to copy DNA. The cell runs out of what it needs and cannot proceed.
Two things tend to come as a surprise. First, the dose. MTX at the amount a rheumatologist prescribes weekly and MTX at the amount used to treat bone cancer are not comparable experiences — same molecule, entirely different treatment. Second, leucovorin. Most patients have not heard of it before their first high-dose cycle. It is a separate drug given in the hours and days after the infusion, specifically to limit damage to healthy tissue. Without it, high-dose treatment would not be survivable. These are worth knowing before the drip goes in.
Whether methotrexate is right at this dose at this point depends on the condition, the kidneys, and what other tablets the patient is already on. Diagnosis is where the conversation starts, not where it ends.
MTX does not go after DNA directly. Inside the cell it blocks a specific enzyme that sits early in the folate pathway — the chain of reactions cells use to produce the raw nucleotides needed for replication. Cut off that supply and the copying process stalls.
Fast-dividing cells hit the wall first. That includes tumour cells, but also the gut lining, the marrow, and the lining of the mouth. Most side effects come from there.
At the low doses used in rheumatology the dominant effect is anti-inflammatory, not cytotoxic. Folate metabolism touches immune regulation as well as cell division. At oncology doses the cytotoxic effect takes over. The molecule is the same; the dose determines what it is primarily doing.
Methotrexate appears across oncology and some other specialties. The oncology uses are the focus here.
Diagnosis opens the conversation. Subtype, disease extent, kidney function, what has already been tried and how it was tolerated — those are what shape the real decision.
Certain clinical situations bring it into focus.
Treatment into the spinal canal and treatment into a vein are not the same thing. Different route, different purpose, different complications. That distinction matters and should be part of the conversation upfront.
The team needs a proper picture before the first dose — not just the protocol name.
Kidney function is more critical here than with almost any other oncology drug. Methotrexate depends on the kidneys to leave the body. Even a modest drop in kidney performance can keep levels elevated far longer than planned and turn a manageable infusion into a toxic event.
The route depends on what is being treated. Into a vein for systemic disease. Into the spinal canal for CNS disease or prophylaxis. By mouth at low doses in some maintenance protocols.
At high oncology doses the infusion runs over several hours, followed by heavy IV fluid and leucovorin starting 24 hours in. Blood levels are drawn repeatedly until they fall to a confirmed safe point. Leucovorin continues until that threshold is reached. Doses across different indications differ enormously.
During treatment the team monitors:
Delays and dose changes happen and are not a sign of failure. Kidney numbers, drug levels, mucositis — any of these can shift timing or amount. Asking why is always reasonable.
Mouth sores tend to be what patients find hardest — and at oncology doses, that concern is usually well founded.
Rare but serious:
Nervous system changes after spinal administration deserve the most active tracking. Memory lapses, concentration problems, mood shifts that develop during or after treatment — not just at the time of injection — should be raised with the team straight away.
Some things during methotrexate treatment should not wait for the next scheduled visit.
When clearance falls behind after a high-dose infusion, drug levels stay up and damage continues past the planned window. Dropping urine output or a blood level higher than expected is a reason to call the team that day, not to wait.
Even when the diagnosis fits and the drug is standard for that condition, methotrexate does not suit every patient at every point.
Methotrexate reacts badly with more drugs than most patients expect. Painkillers from the ibuprofen family slow the rate at which the kidneys remove the drug. Certain penicillins do the same. Some tablets taken for stomach acid affect renal excretion. Trimethoprim, used as an antibiotic, hits the same enzyme the drug targets and makes the effect stronger. Going through every tablet, capsule and supplement before each cycle is not a bureaucratic step — it is how serious toxicity gets prevented.
Rarely given on its own outside a handful of specific situations. In most oncology protocols it runs alongside other drugs.
What methotrexate is combined with changes the full picture. Cytarabine adds marrow suppression. Cisplatin adds hearing and kidney concerns. Leucovorin is what makes high doses possible at all.
Response is not measured after one cycle. It takes several cycles, then imaging, markers and clinical assessment together. A single scan or a single blood result is rarely enough to draw conclusions.
If the disease is clearly progressing, toxicity has become unmanageable, or the regimen is not achieving what it was designed for — the plan needs reviewing. Methotrexate is a tool inside a strategy. When the strategy needs updating, that conversation should happen with the treating oncologist rather than being deferred.
Tel Aviv Medical Clinic offers oncology consultations and second opinions for patients on a methotrexate-based regimen or considering one. Useful when the dose or route has not been properly explained, when a complication has arisen that has not been addressed, when a drug interaction concern has come up, or when the patient wants to understand what alternatives exist.
The consultation can cover:
We do not replace the treating doctor. We help the patient arrive at the next conversation knowing what to ask.
Leucovorin is a folate compound that bypasses the enzyme methotrexate blocks. Normal cells keep functioning while drug levels are still high. Cancer cells do not benefit the same way — they handle leucovorin differently. Missing doses after a high infusion allows the drug to keep damaging normal tissue past the intended window. Gut lining, marrow, kidneys. The timing follows blood levels, not a clock on the wall.
Methotrexate leaves the body almost entirely through one route — the kidneys. Slow that down, even slightly, and levels stay up longer than planned. Leucovorin cannot fully compensate. At high doses the result is gut damage, marrow failure, and kidney injury on top of each other. The gap between a working level and a harmful one closes fast when renal function drops. Testing before each cycle and during the infusion is how that gets caught before it becomes a crisis.
IV methotrexate goes into the bloodstream and reaches most of the body. The central nervous system sits behind a barrier that most drugs — even at high IV doses — do not cross reliably. Spinal administration puts the drug directly into the cerebrospinal fluid through a needle in the lower back. No barrier to cross. The two approaches treat different problems, produce different complications, and are not interchangeable.
The ibuprofen group — and other drugs in that painkiller class — compete with methotrexate for the same exit pathway through the kidneys. Levels rise. Some penicillin antibiotics do the same. Certain tablets prescribed for acid reflux reduce how well the kidneys push methotrexate out. Trimethoprim targets the same enzyme the drug targets and amplifies the whole effect. None of this is labelled obviously. The only way to find the conflicts is to go through every medication, supplement and herbal product before each cycle.
Pathology report, recent scans, surgery notes if relevant, the full list of treatments given and when, methotrexate blood levels from previous cycles if available, recent kidney and liver results. A specific account of any complications — which cycle, what happened, how severe, how it was managed. A complete medication list. For patients who have had spinal treatment, any neurological symptoms that appeared and whether they resolved. That level of detail is what makes the consultation genuinely useful.
This page gives general medical information. It is not a personal treatment plan. Methotrexate should be discussed only after review of the diagnosis, stage, kidney and liver function, current medications and the patient’s overall condition.
Do not start, stop or change chemotherapy without your treating oncologist.
For consultation about Methotrexate treatment:
📞 +972-73-374-6844
💬 WhatsApp: +972-52-337-3108
